4 Heathcare Stock Stories for Investors Not To Miss

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Amgen (NASDAQ:AMGN): Closing price $84.32

On Wednesday, Amgen announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial, which was begun in 2006. A total number of 2,278 patients suffering from symptomatic systolic heart failure and anemia (hemoglobin levels ranging from 9.0-12.0 g/dL) were randomized to receive either treatment with Aranesp to reach a target hemoglobin of a minimum of 13.0 g/dL (not to exceed 14.5 g/dL), or placebo.  The evaluation failed to meet its primary endpoint of reducing the composite endpoint of time to death from any cause or first hospital admission for worsening heart failure.

amg

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business